LPS- and TNF-α–matured DCs cultured in GM-CSF/IL-4 provide comparable protection against murine AML challenge.

DCs were cultured and matured with either LPS or TNF-α and pulsed with AML (C1498) cell lysate for 18 hours then administered intravenously (0.5 × 10⁶ cells/mouse) 14 and 7 days prior to tumor challenge with 2 × 10⁶ C1498 cells/mouse. The mice receiving DC vaccination had significantly improved survival compared with nonvaccinated controls (P < .0001). There was no significant difference (P = .3) between mice receiving LPS- or TNF-α–matured DCs. Data are pooled results of 2 independent experiments (13 total/group).